Preclinical studies have shown that trastuzumab deruxtecan (T-DXd) enhances PD-L1 and MHC-I expression and promotes CD8+ T-cell infiltration in the tumor microenvironment, suggesting potential synergy with ICIs (134–136). Here, CD8A is linked to neoplasm.